Today: 1 March 2026
Subscribe
Browse Category

Mergers and Acquisitions 22 December 2025 - 13 January 2026

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol stock rises as Barclays, Citi and Truist lift targets after CommScope deal closes

Amphenol shares rose 2.2% to $148.28 Tuesday, bucking a broader market decline after finalizing its $10.5 billion acquisition of CommScope’s CCS business. Analysts at Barclays, Citi, and Truist raised price targets, citing expected sales growth and stronger demand. The company projects CCS will add $4.1 billion in 2026 sales and $0.15 to EPS, excluding costs. Quarterly earnings are due Jan. 28.
13 January 2026
···
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum stock (QBTS) slides after $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum shares fell 3.4% to $30.20 after announcing a $550 million deal to acquire Quantum Circuits, split between $250 million cash and $300 million in stock. The agreement uses a VWAP collar to set share count and requires antitrust and NYSE approval. The deal aims to bring superconducting gate-model systems to market in 2026. Trading volume reached 36.5 million shares.
8 January 2026
···
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck shares slipped 0.3% to $108.59 after it completed its tender offer for Cidara Therapeutics and expects to finalize the $9.2 billion acquisition later Wednesday. The deal will add about $9 billion to 2026 R&D expenses and reduce earnings per share by 30 cents in the first year. Merck also began a Phase 3 lung-cancer trial of calderasib with Keytruda QLEX. U.S. officials updated HPV and rotavirus vaccine guidance this week.
7 January 2026
·····
US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

US stock market: Vistra stock pops in premarket on $4.7B Cogentrix deal amid AI power-demand boom

Vistra shares rose 4.4% to $170.17 premarket Tuesday after agreeing to buy Cogentrix Energy from Quantum Capital Group in a deal valued at $4.7 billion. The acquisition adds 5.5 gigawatts of natural gas generation across key U.S. markets and is expected to close in mid-to-late 2026. Vistra said the deal should boost per-share cash flow starting in 2027.
6 January 2026
···
BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel stock jumps 21% on A$30 takeover bid — the next catalyst investors are watching

BlueScope Steel shares jumped 20.6% to A$29.48 after SGH and Steel Dynamics made a non-binding A$30-per-share takeover offer. The proposal, received Dec. 12, is subject to due diligence, exclusivity, and other conditions. BlueScope’s board is reviewing the bid against its own valuation. The company previously rejected lower offers, citing execution risks.
6 January 2026
···
Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber stock slips as SpotHero acquisition-talk report emerges in year-end trade

Uber shares slipped 0.3% to $81.87 after a report said the company has held talks to acquire parking app SpotHero, which was last valued at about $290 million. SpotHero operates in over 400 North American cities. Traders await confirmation of the talks and Uber’s next earnings report, expected Feb. 4. Lyft rose 0.2% while DoorDash fell 0.2% in afternoon trading.
31 December 2025
··
Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

Abivax’s U.S.-listed shares fell 3.8% to $133.04 late Wednesday morning, reversing part of a recent surge driven by takeover speculation and index inclusion. Trading volume reached about 348,000 shares as the stock swung between $132.13 and $140.25. Investors await updates on strategic interest and new data for obefazimod, the company’s lead drug candidate.
31 December 2025
··
Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

Coforge’s $2.35 billion Encora deal tops India’s stocks-to-watch list for Dec. 29

Coforge agreed to acquire U.S.-based Encora for $2.35 billion and will raise up to $550 million via a share sale to fund the deal. Punjab National Bank reported a 24.34 billion-rupee fraud to regulators. Timex Group India’s promoter plans to sell up to 8.93% on Dec. 29–30. GIFT Nifty futures rose 40 points to 26,100 ahead of Monday’s open.
29 December 2025
··
Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

Ondas Holdings (NASDAQ: ONDS) Stock News Today: Defense-Drone Contracts, M&A Momentum, and Fresh Analyst Targets in a Thin Holiday Market

Ondas Holdings Inc. shares fell about 6% to $8.56 by early afternoon Friday, trading on heavy volume over 24 million shares. The drop comes as small-cap stocks lag in a quiet, post-holiday session, with large-cap and tech indexes little changed. Ondas recently announced a major government contract for an autonomous border-protection drone system, with an initial order expected in January 2026.
26 December 2025
···
Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

Zeta Global Holdings traded near $19.12 late Friday morning, little changed after opening at $19.05. The stock showed muted movement as U.S. markets reopened post-Christmas with light volume. Investors continue to weigh Zeta’s recent $325 million Marigold acquisition and raised guidance ahead of CES 2026.
26 December 2025
···
AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

Nvidia has secured a non-exclusive license to Groq’s AI inference chip technology and is hiring Groq’s founder, president, and key engineers, Reuters reports. Groq will continue operating independently under a new CEO. Snowflake is reportedly in talks to acquire Observe for about $1 billion, according to Investors.com, in what would be its largest deal to date.
25 December 2025
······
AI Stocks Today (Dec. 24, 2025, 5:02 p.m. ET): Nvidia’s Reported $20B Groq Deal, Snowflake M&A Talk, and Wall Street’s 2026 AI Outlook

AI Stocks Today (Dec. 24, 2025, 5:02 p.m. ET): Nvidia’s Reported $20B Groq Deal, Snowflake M&A Talk, and Wall Street’s 2026 AI Outlook

Nvidia agreed to acquire AI chip startup Groq for $20 billion in cash, Reuters reported Wednesday, citing CNBC. The S&P 500 and Dow closed at record highs after an early Christmas Eve session, lifted by renewed demand for tech and AI stocks and expectations of Fed rate cuts in 2026. Trading volumes were thin ahead of the holiday.
24 December 2025
··
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Sanofi announced a deal to acquire Dynavax Technologies for $2.2 billion in cash, offering $15.50 per share—a 39% premium to Dynavax’s prior close. DVAX stock jumped about 37% premarket to near the offer price. Dynavax’s board approved the transaction. Closing is expected in Q1 2026, pending regulatory and shareholder approvals.
24 December 2025
···
Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics shares traded at $24.06 on December 23, just below the $24.55-per-share cash buyout price set in an $8.4 billion take-private deal led by Permira and Warburg Pincus. The agreement includes a go-shop period through January 23, 2026, allowing Clearwater to seek higher offers.
23 December 2025
·
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. FOLD traded near $14.22 on December 22, reflecting market expectations for deal completion and timing. The transaction is expected to close in Q2 2026, pending regulatory and shareholder approvals. Either party may terminate if not closed by June 19, 2026, with a $175 million breakup fee.
22 December 2025
··
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

Abivax shares jumped as much as 14% to €114.4 in Paris on Monday after reports of renewed takeover interest from Eli Lilly and the company’s addition to the Nasdaq Biotechnology Index. French outlet La Lettre reported Lilly representatives met with French Treasury officials this month about a potential deal, though Reuters said it could not confirm the meeting. Neither company commented on the rumors.
22 December 2025
··
1 2 3 4 … 6
Go toTop